Influential factors of voriconazole trough concentration and AUC in pediatric patients with thalassemia undergoing hematopoietic stem cell transplantation

LIU Yongjun; WU Yun; LING Yayun; NIU Lulu; HUANG Tianmin; CHEN Xin; LUO Yilin; LIU Taotao

doi:10.6039/j.issn.1001-0408.2024.20.10

您当前的位置：

首页 >

文章列表页 >

Influential factors of voriconazole trough concentration and AUC in pediatric patients with thalassemia undergoing hematopoietic stem cell transplantation

更新时间：2024-10-25

- Influential factors of voriconazole trough concentration and AUC in pediatric patients with thalassemia undergoing hematopoietic stem cell transplantation
- ZHONGGUO YAOFANG Vol. 35, Issue 20, Pages: 2499-2504(2024)
- 作者机构：
  
  1.广西医科大学第一附属医院药学部，南宁　530021
  2.广西医科大学第一附属医院儿科，南宁　530021
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.20.10
  CLC： R969.3;R978.5
- Published：30 October 2024，
  
  Received：18 April 2024，
  
  Revised：02 September 2024，
- 稿件说明：
移动端阅览
刘勇军,伍云,凌雅赟等.地中海贫血患儿造血干细胞移植术后伏立康唑谷浓度及AUC的影响因素分析 ^Δ[J].中国药房,2024,35(20):2499-2504.

LIU Yongjun,WU Yun,LING Yayun,et al.Influential factors of voriconazole trough concentration and AUC in pediatric patients with thalassemia undergoing hematopoietic stem cell transplantation[J].ZHONGGUO YAOFANG,2024,35(20):2499-2504.
刘勇军,伍云,凌雅赟等.地中海贫血患儿造血干细胞移植术后伏立康唑谷浓度及AUC的影响因素分析 ^Δ[J].中国药房,2024,35(20):2499-2504. DOI： 10.6039/j.issn.1001-0408.2024.20.10.

LIU Yongjun,WU Yun,LING Yayun,et al.Influential factors of voriconazole trough concentration and AUC in pediatric patients with thalassemia undergoing hematopoietic stem cell transplantation[J].ZHONGGUO YAOFANG,2024,35(20):2499-2504. DOI： 10.6039/j.issn.1001-0408.2024.20.10.

摘要

目的

分析地中海贫血患儿造血干细胞移植（HSCT）术后伏立康唑（VRZ）谷浓度（

min

）和药时曲线下面积（AUC）的影响因素。

方法

选择2021年1月至2024年1月于我院接受HSCT并使用VRZ预防或治疗侵袭性真菌感染的地中海贫血患儿60例，采用高效液相色谱法测定VRZ的血药浓度并计算AUC；采用多元线性回归分析影响VRZ

min

、AUC的独立因素。

结果

共得到60例患儿的120例次VRZ

min

，26例患儿的27例次VRZ AUC。VRZ

min

的中位浓度是0.31 mg/L，其中0.5～5 mg/L有46例次（38.33%），＞5 mg/L有2例次（1.67%），＜0.5 mg/L有72例次（60.00%）；VRZ AUC的中位数是11.68 mg·h/L。患儿体重、HSCT术后时间、淋巴细胞计数以及是否合用苯妥英钠、他克莫司、环孢素对VRZ

min

有显著影响（

＜0.05）；淋巴细胞计数和是否合用苯妥英钠对VRZ AUC有显著影响（

＜0.05）。

结论

患儿体重、HSCT术后时间、淋巴细胞计数以及是否合用苯妥英钠、他克莫司、环孢素是影响VRZ

min

的独立因素，淋巴细胞计数、是否合用苯妥英钠是影响VRZ AUC的独立因素。

Abstract

OBJECTIVE

To analyze the influential factors on trough concentration （

min

） and area under the drug concentration time curve （AUC） of voriconazole （VRZ） in pediatric patients with thalassemia undergoing hematopoietic stem cell transplantation （HSCT）.

METHODS

A total of 60 pediatric patients with thalassemia undergoing HSCT who used VRZ for prevention or treatment of invasive fungal infection were collected in our hospital from January 2021 to January 2024. The plasma concentration of VRZ was measured by high-performance liquid chromatography and the AUC was calculated. The factors affecting

min

and AUC of VRZ were analyzed using multiple linear

regression.

RESULTS

A total of 120 cases of VRZ

min

in 60 pediatric patients was obtained and 27 cases of VRZ AUC in 26 pediatric patients were obtained. The median concentration of VRZ

min

was 0.31 mg/L； 46 cases had a

min

in 0.5-5 mg/L

（38.33%）， 2 cases had a

min

＞5 mg/L

（1.67%）， and 72 cases had a

min

＜0.5 mg/L. The median AUC of VRZ was 11.68 mg·h/L. The patient’s body weight， HSCT postoperative days， lymphocyte count， and combined use of phenytoin sodium， tacrolimus or cyclosporine had significant effects on VRZ

min

（

＜0.05）. Lymphocyte count and combined use of phenytoin sodium had significant effects on VRZ AUC （

＜0.05）.

CONCLUSIONS

The body weight， HSCT postoperative days， lymphocyte count， and combined use of phenytoin sodium， tacrolimus or cyclosporine are independent factors affecting VRZ

min

. Lymphocyte count and combined use of phenytoin sodium are independent factors affecting VRZ AUC.

关键词

伏立康唑地中海贫血造血干细胞移植血药浓度谷浓度药时曲线下面积影响因素

Keywords

thalassemiahematopoietic stem cell transplantationplasma concentrationtrough concentrationarea under the drug concentration-time curveinfluential factors

references

WANG W D，HU F，ZHOU D H，et al. Thalassaemia in China[J]. Blood Rev，2023，60：101074.

马蕾，钟沂芮，刘林，等. 造血干细胞移植后侵袭性真菌病临床特点及危险因素分析[J]. 第三军医大学学报，2020，42（17）：1735-1742.

MA L，ZHONG Y R，LIU L，et al. Clinical characteristics and risk factors of invasive fungal disease after hemato-poietic stem cell transplantation：report of 233 cases[J]. J Third Mil Med Univ，2020，42（17）：1735-1742.

TEH B W，YEOH D K，HAEUSLER G M，et al. Consensus guidelines for antifungal prophylaxis in haemato-logical malignancy and haemopoietic stem cell transplantation，2021[J]. Intern Med J，2021，51（Suppl. 7）：67-88.

LEHRNBECHER T，FISHER B T，PHILLIPS B，et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients[J]. J Clin Oncol，2020，38（27）：3205-3216.

SCHULZ J，KLUWE F，MIKUS G，et al. Novel insights into the complex pharmacokinetics of voriconazole：a review of its metabolism[J]. Drug Metab Rev，2019，51（3）：247-265.

HANAI Y，HAMADA Y，KIMURA T，et al. Favorable effects of voriconazole trough concentrations exceeding 1 μg/mL on treatment success and all-cause mortality：a systematic review and meta-analysis[J]. J Fungi，2021，7（4）：306.

HUURNEMAN L J，NEELY M，VERINGA A，et al. Pharmacodynamics of voriconazole in children：further steps along the path to true individualized therapy[J]. Antimicrob Agents Chemother，2016，60（4）：2336-2342.

PEA F. From bench to bedside：perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis[J]. Mycoses，2020，63（8）：854-858.

CHEN K，ZHANG X L，KE X Y，et al. Individualized medication of voriconazole：a practice guideline of the Division of Therapeutic Drug Monitoring，Chinese Pharmacological Society[J]. Ther Drug Monit，2018，40（6）：663-674.

陈娟，何岳林，冯晓勤，等. 造血干细胞移植患儿伏立康唑治疗药物浓度监测及影响因素分析[J]. 今日药学，2021，31（10）：769-773.

CHEN J，HE Y L，FENG X Q，et al. Therapeutic drug monitoring and influencing factors of voriconazole serum concentration in pediatric hematopoietic stem cell transplantation patients[J]. Pharm Today，2021，31（10）：769-773.

MORIYAMA B，OBENG A O，BARBARINO J，et al. Clinical Pharmacogenetics Implementation Consortium（CPIC） guidelines for CYP2C19 and voriconazole therapy[J]. Clin Pharmacol Ther，2017，102（1）：45-51.

WU Q，ZHOU Y，FAN X，et al. Evaluation of nine formulas for estimating the body surface area of children with hematological malignancies[J]. Front Pediatr，2022，10：989049.

NDREPEPA G，HOLDENRIEDER S，NEUMANN F J，et al. Prognostic value of glomerular function estimated by Cockcroft-Gault creatinine clearance，MDRD-4，CKD-EPI and European Kidney Function Consortium equations in patients with acute coronary syndromes[J]. Clin Chim Acta，2021，523：106-113.

GABRIELSSON J，WEINER D. Non-compartmental analysis[J]. Methods Mol Biol，2012，929：377-389.

WALSH T J，KARLSSON M O，DRISCOLL T，et al. Pharmacokinetics and safety of intravenous voriconazole in children after single or multiple-dose administration[J]. Antimicrob Agents Chemother，2004，48（6）：2166-2172.

DRISCOLL T A，YU L C，FRANGOUL H，et al. Com-parison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults[J]. Antimicrob Agents Chemother，2011，55（12）：5770-5779.

SHI C C，XIAO Y B，MAO Y，et al. Voriconazole：a review of population pharmacokinetic analyses[J]. Clin Pharmacokinet，2019，58（6）：687-703.

BARTELINK I H，WOLFS T，JONKER M，et al. Highly variable plasma concentrations of voriconazole in pedia-tric hematopoietic stem cell transplantation patients[J]. Antimicrob Agents Chemother，2013，57（1）：235-240.

WU Y，LV C L，WU D N，et al. Dosage optimization of voriconazole in children with haematological malignancies based on population pharmacokinetics[J]. J Clin Pharm Ther，2022，47（12）：2245-2254.

ZHAO Y C，LIU H Y，XIAO C L，et al. Enhancing voriconazole therapy in liver dysfunction：exploring administration schemes and predictive factors for trough concentration and efficacy[J]. Front Pharmacol，2023，14：1323755.

DUNVALD A D，JÄRVINEN E，MORTENSEN C，et al. Clinical and molecular perspectives on inflammation-mediated regulation of drug metabolism and transport[J]. Clin Pharmacol Ther，2022，112（2）：277-290.

彭新国，孙长华，安佳佳，等. 异基因造血干细胞移植后细胞免疫重建与真菌感染的相关性[J]. 检验医学，2020，35（5）：447-450.

PENG X G，SUN C H，AN J J，et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation and its correlation with fungal infection[J]. Lab Med，2020，35（5）：447-450.

王陶陶，胡萨萨，尤海生，等. 恶性血液病患者中伏立康唑血药浓度监测及其影响因素的探讨[J]. 中国医院药学杂志，2018，38（7）：693-696，707.

WANG T T，HU S S，YOU H S，et al. Monitoring voricona-zole concentrations and identifying the influence factors in patients with hematological malignancy[J]. Chin J Hosp Pharm，2018，38（7）：693-696，707.

HAN K L，CAPITANO B，BIES R，et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients[J]. Antimicrob Agents Chemother，2010，54（10）：4424-4431.

JOHNSON H J，HAN K L，CAPITANO B，et al. Voricona-zole pharmacokinetics in liver transplant recipients[J]. Antimicrob Agents Chemother，2010，54（2）：852-859.

CZYRSKI A，RESZTAK M，ŚWIDERSKI P，et al. The overview on the pharmacokinetic and pharmacodynamic interactions of triazoles[J]. Pharmaceutics，2021，13（11）：1961.

ZACCARA G，LATTANZI S. A review of pharmacokinetic drug interactions between antimicrobial and antiseizure medications in children[J]. Epileptic Disord，2021，23（2）：229-256.

ZENG G T，SHI L H，LI H L，et al. Effect of cyclosporine A and polymorphisms in CYP2C19 and ABCC2 on the concentration of voriconazole in patients undergoing allogeneic hematopoietic stem cell transplantation[J]. Xenobiotica，2020，50（5）：614-619.

杨梦婕，王梅，桂环. 造血干细胞移植儿童体内伏立康唑与钙调神经磷酸酶抑制剂的相互作用[J]. 儿科药学杂志，2021，27（12）：23-25.

YANG M J，WANG M，GUI H. Interaction between voriconazole and calcineurin inhibitors in children undergoing hematopoietic stem cell transplantation[J]. J Pediatr Pharm，2021，27（12）：23-25.

AMUNDSEN R，ÅSBERG A，OHM I K，et al. Cyclosporine A and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro[J]. Drug Metab Dispos，2012，40（4）：655-661.

FAN X H，ZHANG H，WEN Z P，et al. Effects of CYP2C19，CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients[J]. Pharmacogenet Genomics，2022，32（4）：152-158.

ZHANG Y，HOU K L，LIU F，et al. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations：systematic review and meta-analysis[J]. Mycoses，2021，64（8）：860-873.

LI Z W，PENG F H，YAN M，et al. Impact of CYP2C19 genotype and liver function on voriconazole pharmacokinetics in renal transplant recipients[J]. Ther Drug Monit，2017，39（4）：422-428.

张瑞霞，张艳，张弋，等. 伏立康唑谷浓度在血液科患者中的分布特征及影响因素[J]. 中国药物应用与监测，2019，16（4）：204-207.

ZHANG R X，ZHANG Y，ZHANG Y，et al. Distribution characteristics and influencing factors of voriconazole trough concentration in hematological patients[J]. Chin J Drug Appl Monit，2019，16（4）：204-207.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Investigation of the causes and analysis of influencing factors about interruption of menopausal hormone therapy

Analysis of influential factors for purchasing quantity changes in the procurement varieties of the first batch of drug centralized procurement

The characteristics and influencing factors of medicine cost for orthopedic surgery patients in hospitals of Shanxi province

Analysis of DRG grouping effect and influential factors of hospitalization cost of diabetic patients

Analysis of the burden of polypharmacy and its influencing factors among elderly tuberculosis patients in Guizhou province

Related Author

ZHOU Ting

PENG Xueyao

ZHAN Xia

BAO Hongrong

LIU Yuxin

WEN Xiaotong

DUAN Fengran

WANG Yue

Related Institution

Dept. of Pharmacy， Lin’an District First People’s Hospital of Hangzhou

Dong Fureng Institution of Economic and Social Development， Wuhan University

Global Health Institute， Wuhan University

School of Public Health， Wuhan University

School of Nursing， Tongji Medical College of Huazhong University of Science and Technology

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰